| 2026-08-12 | Presentation | Corporate Presentation - August 12, 2026 |
| 2026-08-12 | Press release | Kura Oncology Reports Second Quarter 2026 Financial Results |
| 2026-08-10 | Press release | Kura Oncology Announces Publication in Blood Highlighting Ziftomenib’s Differentiated Binding Profile and Preclinical Ac |
| 2026-08-07 | Press release | Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-08-05 | Press release | Kura Oncology to Report Second Quarter Financial Results |
| 2026-07-27 | Presentation | KCRS Investor Presentation - July 27, 2026 |
| 2026-07-27 | Press release | Kura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naïve Clear Cell Renal |
| 2026-07-14 | Press release | Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targ |
| 2026-07-03 | Press release | Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-06-12 | Presentation | EHA Investor Presentation - June 12, 2026 |
| 2026-06-11 | Press release | Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed A |
| 2026-06-05 | Press release | Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-06-03 | Press release | Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outl |
| 2026-06-03 | Presentation | ASCO Investor Presentation - June 3, 2026 |
| Press release | Kura Oncology Reports First Quarter 2026 Financial Results |
| 2026-05-12 | Presentation | Corporate Presentation - May 12, 2026 |
| Press release | Kura Oncology to Report First Quarter 2026 Financial Results |
| 2026-04-17 | Presentation | IKCS Virtual Investor Event - April 17, 2026 |
| 2026-03-05 | Press release | Kura Oncology Reports Fourth Quarter and Full Year 2025 Financial Results |
| 2026-02-26 | Press release | Kura Oncology to Report Fourth Quarter and Full Year 2025 Financial Results |
| 2025-12-08 | Presentation | ASH Investor Presentation - December 8, 2025 |
| 2025-11-13 | Presentation | KOMZIFTI FDA Approval - November 13, 2025 |
| Press release | Kura Oncology Reports Third Quarter 2025 Financial Results |
| Press release | Kura Oncology to Report Third Quarter 2025 Financial Results |
| 2025-10-18 | Presentation | Farnesyl Transferase Program Review – Clinical Update from ESMO 2025 – Oct. 18, 2025 |
| 2025-09-16 | Presentation | FTI Preclinical Program Review: Synergistic Combinations with Targeted Therapies – Sept. 16, 2025 |
| Press release | Kura Oncology Reports Second Quarter 2025 Financial Results |
| Press release | Kura Oncology to Report Second Quarter 2025 Financial Results |
| 2025-06-18 | Presentation | EHA Investor Presentation – June 18, 2025 |
| 2025-06-02 | Presentation | ASCO Investor Presentation – June 2, 2025 |
| Press release | Kura Oncology Reports First Quarter 2025 Financial Results |
| 2025-05-01 | Presentation | Kura Oncology – Corporate Presentation – May 2025 |
| Press release | Kura Oncology to Report First Quarter 2025 Financial Results |
| Press release | Kura Oncology Reports Fourth Quarter and Full Year 2024 Financial Results |
| Press release | Kura Oncology to Report Fourth Quarter and Full Year 2024 Financial Results |
| Press release | Kura Oncology Reports Third Quarter 2024 Financial Results |
| Press release | Kura Oncology to Report Third Quarter 2024 Financial Results |
| Press release | Kura Oncology Reports Second Quarter 2024 Financial Results |
| Press release | Kura Oncology to Report Second Quarter 2024 Financial Results |
| Press release | Kura Oncology Reports First Quarter 2024 Financial Results |